Quick Summary

Chinese Hawthorn (Crataegus pinnatifida) is a medicinal food homology plant widely used in traditional Chinese medicine. It contains multiple bioactive compounds such as flavonoids and triterpenoids. Research has explored its potential for supporting cardiovascular health, metabolic syndrome, liver conditions, and cancer, though clinical evidence remains preliminary and generally limited by varying study quality and heterogeneity. Safety data indicate it is generally well tolerated with minor and uncommon adverse effects.

What is it?

Chinese Hawthorn is a species of hawthorn native to China, traditionally used both as food and medicine. Its fruit and leaves contain active compounds that have been studied for a range of biological activities. In traditional Chinese medicine, it is regarded as a beneficial herb for strengthening digestion and promoting heart health.

Traditional Uses

Traditionally, Chinese Hawthorn has been utilized to support cardiovascular function, improve digestion, and address symptoms associated with blood stasis and poor circulation. It is also used as a dietary supplement to aid metabolic health and liver function.

Active Compounds

The herb contains various bioactive constituents, including:

  • Flavonoids (such as hyperoside)
  • Triterpenoids
  • Phenolic acids
  • Proanthocyanidins

These compounds are thought to contribute to the herb’s antioxidant, anti-inflammatory, and metabolic effects.

Potential Benefits with Evidence Levels

  • Cardiovascular health (Moderate evidence): Some clinical trials and reviews suggest Chinese Hawthorn may improve symptom scores, lipid profiles, inflammatory markers, and cardiac function in conditions like atherosclerosis and angina pectoris. However, evidence includes inconsistencies and risk of bias.
  • Metabolic Conditions (Low to Moderate evidence): Meta-analyses of traditional Chinese medicine formulations containing Chinese Hawthorn indicate potential benefits on glucose regulation, lipid metabolism, insulin resistance, and liver function in type 2 diabetes and metabolic-associated fatty liver disease, although heterogeneity limits firm conclusions.
  • Lipid metabolism and dyslipidemia (Moderate evidence): Randomized controlled trials and meta-analyses report improvements in cholesterol levels, including reductions in total cholesterol, LDL-C, and triglycerides, and increases in HDL-C from Chinese patent medicines containing Chinese Hawthorn.
  • Anti-inflammatory and antioxidant effects (Preclinical and exploratory clinical evidence): Flavonoids and other compounds show anti-inflammatory and antioxidant activity in vitro and animal models. These properties might contribute to observed clinical effects, though high-quality human studies are limited.
  • Potential anticancer effects (Preclinical and early clinical evidence): Network pharmacology and literature reviews identify possible anticancer mechanisms via multiple signaling pathways, but clinical evidence remains preliminary and insufficient for recommendations.

Side Effects

Chinese Hawthorn products are generally well tolerated. Reported adverse effects are mostly mild and infrequent, including:

  • Minor gastrointestinal discomfort
  • Skin and subcutaneous tissue disorders (e.g., rash)
  • Occasional mild cardiac-related events

No serious or consistent safety signals have been observed in pharmacovigilance data or clinical trials.

Drug Interactions

There are no strong clinical data confirming specific drug interactions with Chinese Hawthorn. However, because it may affect cardiovascular function and platelet aggregation, caution is advised when combined with anticoagulants or antiplatelet agents. Further research is needed to clarify these potential interactions.

Who Should Avoid It

  • Individuals with known hypersensitivity or allergy to Crataegus species or its components should avoid use.
  • Use caution in patients with severe cardiac conditions; medical supervision is recommended.
  • Pregnant or breastfeeding women should avoid Chinese Hawthorn due to insufficient safety data.

Evidence Limitations

  • Many clinical trials have moderate to high risk of bias, small sample sizes, and use heterogeneous herbal formulations.
  • Systematic reviews frequently downgrade evidence certainty due to inconsistency and imprecision.
  • Most pharmacological data come from preclinical or in vitro studies with limited rigorous clinical validation.
  • Safety data primarily derive from case reports and pharmacovigilance databases with inherent limitations.
  • Lack of large-scale, high-quality randomized controlled trials to definitively establish efficacy and safety.

References

Last Reviewed

April 2024

Disclaimer

This information is for educational purposes only and is not intended to replace professional medical advice. Chinese Hawthorn and its preparations are not approved by regulatory authorities for the treatment or prevention of any medical conditions. Consult your healthcare provider before using this herb, especially if you have underlying health issues or are taking medications.